Luke Evans MP: speeches

Speeches

• 30 Jun 2026 · Topical Questions · Hansard source

  More

  The Fuller inquiry called for a strengthening of the safeguards and the law in relation to looking after the deceased, but last week’s mortuary report on Nottingham hospital described some of the abuses and horrors that have taken place—bodies mislabelled, or even left decomposing. Does the Secretary of State share my fear that this could be a pattern across the system, and will he and the Health Secretary look into this to ensure that it certainly is not?

• 30 Jun 2026 · Topical Questions · Hansard source

  More

  T1. If he will make a statement on his departmental responsibilities.

• 30 Jun 2026 · Department of Health and Social Care · Hansard source

  More

  The Minister would save a lot of time simply by publishing the impact assessment, which would answer every one of the questions that she is trying to find the answers to in her folder, so will she—yes or no?

• 30 Jun 2026 · Department of Health and Social Care · Hansard source

  More

  Or guesstimates day, for want of a better pun. That is part of the problem. If the Government are so confident, why do they not produce the impact report so that they can justify this? At the end of the day, we have seen that those decisions are not isolated; they are different companies, making different decisions, but all with the same concern. It is a pattern: tax rises, more regulation, more red tape—a more toxic concoction. The Government will say that the deal is part of the answer, but Ministers cannot point to potential benefits while avoiding certain costs. The House of Commons Library is clear that the Department’s main estimate for 2026-27 does not include budget cover to meet the expected increase in pharmaceutical spending associated with the UK-US arrangement. That is the central problem. The Government say that the total cost in the current spending review period is expected to be around £1 billion, but the former Minister, the hon. Member for Glasgow South West (Dr Ahmed), also said, “Total costs over the Spending Review period are expected to be approximately £1 billion. The final costs will depend on which medicines NICE recommends and the actual uptake of these.” That is an important admission, because the final cost depends on future NICE decisions and uptake, and other estimates are higher. The Library briefing cites analysis suggesting that spending could be around £1.7 billion by the end of 2028, and around £14 billion by 2036, depending on the assumptions. Is the £1 billion the central estimate, and if so, what are the lower and higher ends of the estimate range? Why will the Government not publish the modelling so that we can see? My next question is even sharper: where is the money coming from? We know from leaked WhatsApp messages that Labour MPs have been asking who they can tax to pay for benefits, so where is the money coming from? Both the House and the public are right to ask. The Government have said that additional costs will be funded from existing NHS budgets, with future funding settled at the next spending review. However, if the money is coming from existing NHS budgets, it is coming from somewhere within the NHS. It might be the workforce, services, capital or future growth, but it will not be cost free. As Jonathan Benger, the chief executive of NICE, put it, “If they choose to spend money on defence, they’ve got to pay for that somehow, either by raising taxes or removing money from somewhere else. If they choose to spend money more on medicines, similarly, that has to be paid for.” That is the reality. The former Secretary of State told the House that the Government would not cut NHS budgets to fund the pharma deal, but the former Health Minister, the hon. Member for Glasgow South West, later turned around and said: “The deal will be funded by allocations made at the Spending Review, where record funding for the NHS was secured. Future funding will be settled at the next Spending Review.” Those statements need reconciling. If it is funded from NHS allocations, that is NHS money. Can the Minister rule out any cuts from the frontline? Finally, I will turn to transparency. I want to point out that the UK-US pharmaceutical arrangement is not a treaty-based free trade agreement. It has not been through the Constitutional Reform and Governance Act process. We have not seen what is going on. The Government need to publish their impact assessment, and yet they cite commercial sensitivity. Of course, there is a way round that: the Minister could redact it and give that to the Committee so that we and this House can see what is going on. I will cut my speech short there. I will simply pose—

• 30 Jun 2026 · Department of Health and Social Care · Hansard source

  More

  I will dispense with the formalities to jump straight in. The hon. Member for Oxford West and Abingdon (Layla Moran) asked whether the Government have a clear, funded and transparent plan. Simply put, the Government appear to have made commitments they cannot properly explain, cannot fully cost, and cannot tell Parliament how they intend to pay for. We are of course talking about the UK-US pharmaceutical arrangement, which will see 0.3% of GDP in 2026, rising to at least 0.6% by 2036—or an overall medicine spend of 10% to 12% of the UK NHS budget by 2036. That may bring benefits and investment, it may avoid tariffs, and it may help some patients get treatment faster, but those benefits do not remove the three key basic questions: what will this cost, how will it be funded, and what will the NHS have to forgo as a consequence? Those questions remain unanswered, which is a running theme from this Government. Since Labour took office in July 2024, the pharmaceutical sector has issued a serious set of stark warnings. In January 2025, AstraZeneca cancelled its £450 million expansion near Liverpool, citing as a factor in the decision “the timing and reduction of the final offer compared to the previous Government's proposal”. However, that was not isolated. In March 2025, the leaders of some of the UK’s biggest pharmaceutical companies warned that the country risked becoming “uninvestable”. That warning turned into decisions, with MSD cancelling its plans for a £1 billion research centre in London, Eli Lilly pausing its work on the Gateway Labs hub, and Sanofi saying that it would not make substantial UK R&D investment until it saw appropriate recognition of the value of innovation.

• 30 Jun 2026 · Department of Health and Social Care · Hansard source

  More

  Will the Minister give way?

• 30 Jun 2026 · Department of Health and Social Care · Hansard source

  More

  What is the policy’s true cost? How will it be paid for? What will be displaced in the NHS to make it happen?

• 25 Jun 2026 · National Lung Cancer Screening Programme · Hansard source

  More

  I appreciate that this is not part of the Minister’s brief. The speed of the programme’s roll-out is fantastic, but there remains a concern that if 60% of people have taken it up, 40% have not done so, despite having had an offer that could have been given to someone else who wanted to go. Can the Department take that point away and work out what is being done to close that gap of more than a third? There is clearly a greater opportunity to get more people in and get them detected sooner.

• 25 Jun 2026 · National Lung Cancer Screening Programme · Hansard source

  More

  It is a pleasure to be here in an air-conditioned room while we continue this debate. It is poignant that it is so hot today, because we know how that can impact people with respiratory illnesses; we are probably talking about this issue at a very useful time. I too thank the hon. Member for Wokingham (Clive Jones) for securing this important debate. As has been said, lung cancer remains a leading cause of cancer death in the UK, but it is also one of the cancers where early detection can make the biggest difference. I know that at first hand from my first year as a junior doctor working on a respiratory ward. It was eye-opening and harrowing, but also sometimes successful. I urge anyone who has the chance to visit a respiratory ward to see how important it is—and I believe that would make a difference to smoking rates. It is great that the hon. Member for Wokingham secured the debate, and great to see the hon. Member for Strangford (Jim Shannon) secured the debate, because it is a good debate—it is a good day. This is really a success story. The Liberal Democrat spokesperson, the hon. Member for Didcot and Wantage (Olly Glover), rightly told us John’s story; because of the screening that has been put in place, there will be plenty more Johns in the future, which is exactly what we want to hear. Often we talk about the problems, but this is a really good example of something positive that has come forward, and it all started under the previous Conservative Government. The roll-out of community diagnostic centres has fundamentally changed how we diagnose disease. There are now more than 170 centres across England, expanding capacity and bringing scans closer to where people live. Nationally, they have delivered millions upon millions of additional tests and have helped to ease pressure on acute services, with the clear aim of diagnosing conditions such as cancer faster and improving patient outcomes. Only this month I went to the first year anniversary of the opening of the CDC in Hinckley, a £24 million investment that has seen 59,000 patients through its door and is expanding. That means patients do not have to travel as far into Leicester or Nuneaton, and that they get their diagnoses more quickly and in a modern tech building. That is absolutely fantastic for my community, but I know that is replicated 170 times across the country. That matters because, when it comes to diseases like lung cancer, early diagnosis is everything. The sooner we can identify a problem, the sooner we can act, and crucially, the better the chances of survival. There is a real success story to talk about. The NHS lung cancer screening programme has its roots in work started by the Conservative Government, building on more than a decade of UK research and pilot studies. Following successful trials and local pilots, NHS England launched the targeted lung health check programme in 2019, focusing on high-risk groups in areas with the worst outcomes. That approach, using mobile scanners and proactive interventions, proved effective in detecting cancer earlier and reaching underserved communities. On the back of that success, and with a formal recommendation from the UK National Screening Committee in 2022, the Government announced a national roll-out in June 2023, committing to expand the screening across England and ultimately to reach full coverage by 2030. Since then, the programme has transitioned from pilots to a full national screening service and now forms a central part of efforts to improve cancer survival. I am pleased to see that the Government are continuing on that trajectory. Why does this matter? The NHS lung cancer screening programme is now delivering at scale and showing clear results. About 2.8 million people have been invited, with 1.5 million checks completed and close to 1 million scans carried out. Some 6,000 to 7,000 cancers have been detected, roughly three quarters of which have been identified at stage 1 or 2, the earlier stages, in comparison with fewer than 30% before the programme started. About 1.4% of the scans lead to a diagnosis, demonstrating a targeted and efficient approach, and uptake stands at about 60%. In short, the programme is not only reaching those most at risk, but consistently shifting diagnosis to an earlier, more treatable stage and saving lives at a national level. As I say, we welcome the proposed expansion of the lung cancer screening programme, but it is vital that steps be taken to improve the uptake of screening and lung health checks. The fact that uptake stands at 60% means that 40% of those invited are not coming forward, and they are often the ones at highest risk. The question is why. Can the Minister set out what specific interventions the Government will introduce to increase uptake, particularly among the most deprived and hard-to-reach groups? To that end, can he confirm how the Government plan to deliver targets set in the national cancer plan, including the allocation of resources and funding for the lung cancer screening programme, over the next few years? As my new Scottish Conservative colleague, my hon. Friend the Member for Aberdeen South (Douglas Lumsden), may rightly point out, progress on lung cancer screening is uneven. England is now rolling out a full national programme; Wales has committed to an implementation, with the first invitations expected from 2027; Scotland remains at a pilot stage, with a national roll-out likely to be years away; and Northern Ireland is still in the early planning phases, without a programme in place. Given that variation, will the Minister set out what discussions are taking place across all four nations? Most importantly, what lessons are been learned from the English experience that can be actively shared to support a faster and more consistent delivery and roll-out across the UK? More broadly, this issue speaks to the need for a coherent approach to respiratory disease. Under the last Conservative Government, there was a clear attempt to take a more joined-up approach to the country’s biggest killers through a major condition strategy, which was announced in 2023. It explicitly placed chronic respiratory diseases, alongside cancer and cardiovascular disease, as one of six national priorities, recognising both its scale—it affects millions—and its contribution to avoidable ill health. A detailed framework, setting out a shift towards prevention, early diagnosis and management of those conditions, was published later that year. However, although the direction of travel was established and widely consulted on, the strategy never reached full publication or implementation, because there was a general election. This Government have taken a different route, with modern service frameworks. They have committed to developing modern service frameworks for frailty, dementia, mental health and cardiovascular disease—just a few areas—so I ask the Minister directly: will the Government develop a modern service framework for respiratory disease? If not, how do they intend to drive the same level of improvement for a condition that affects millions and underpins outcomes in lung cancer? We are all serious about improving cancer survival. Across this House, we all have that ambition, but we must match our ambition with delivery. Just like the 10-year plan, the delivery chapter is missing. I worry that the same could be argued for respiratory conditions. I just hope that I am proved wrong.

• 24 Jun 2026 · Engagements · Hansard source

  More

  Did you meet Andy?

• 23 Jun 2026 · Topical Questions · Hansard source

  More

  T3. Will the Chancellor explain why she is now clawing back VAT on the compassionate medicines scheme, which means that this Labour Government are taxing free cancer drugs given to children? Will she reverse that decision? Patients are starting to miss out on the treatments they really need.

• 16 Jun 2026 · Community Hospitals · Hansard source

  More

  The Government have set out a great ambition, but the Minister is talking about neighbourhood health centres and we are talking about community hospitals. Where do they dovetail and how do they fit? What definition is she using to put this together?

• 16 Jun 2026 · Community Hospitals · Hansard source

  More

  I am sorry to hammer this home, but every single point that the Minister has made has been about community services. She is spot on, but the question is where community hospitals fit in. Are they the correct vehicle that the Government want to use to help deliver some of those services, or are the Government moving away from the community hospital model and into further hubs? Both would be reasonable approaches and could be defended or pulled apart. The question is what the Government are choosing, because it is not clear from the Minister’s answers which it is.

• 16 Jun 2026 · Community Hospitals · Hansard source

  More

  It is a pleasure to serve under your chairmanship, Sir Jeremy. I congratulate the hon. Member for South Cotswolds (Dr Savage) on securing the debate. It is fantastic to have the chance to champion community hospitals and what they stand for and provide. I put on record my thanks to the Hinckley and Bosworth Community Hospital, which does fantastic work in my area, in Hinckley. Also, only last week, I was lucky enough to go to the one-year anniversary celebration for my community diagnostics centre—a £24 million investment, set up by the last Government, that we have now carried through. To date, it has served more than 59,000 patients, and it is expanding the delivery of services that it can provide, meaning that services that are provided within the community and people do not have to travel to the likes of Nuneaton or into Leicester. That is exactly what the leftward shift is all about: bringing those services to the community. It may come as no surprise that I have a personal connection to community hospitals—you might expect me to talk about my job, Sir Jeremy, but it actually began much before that. My father was a GP down in Dorset; on Christmas days, before we were allowed to open our presents, we used to visit the community hospital and do the ward round with all the patients. As a child I really looked forward to that—first, because I got to meet Father Christmas, but secondly, because of the family feel of that community hospital had. That is the essence of what these places provide: that ability to be within our communities, to give the support and the family feel that we want to keep hold of and treasure because it is so important. Especially when dealing with healthcare, we often forget about wellbeing, and that is what these community hubs can provide. Looking at the Government’s direction of travel, it very much sets out how neighbourhood health centres should look, but it is not quite so clear about how that dovetails with community hospitals. How do integrated health hubs fit in with community hospitals? It is not clear in the 10-year plan, and it is certainly not clear in the documentation coming out. Given that the Government are expecting ICBs to commission those hubs, and given some of the stories that we have heard—for example from my hon. Friend the Member for Bognor Regis and Littlehampton (Alison Griffiths), who is championing and fighting for the services in her area—the worry is that the Government are not explicit on what ICBs should be doing on community hospitals. We have this intention and general belief, but the actual direction of how this will work is clouded. I therefore pose a question to the Government: are they considering a national strategy for community hospitals—or even a definition? That is one of the biggest problems when we look up community hospitals. What is the definition of a community hospital? Are community diagnostic centres included in that, or not? What about intermediate care? What about step-down care? What about clinics that provide endoscopy? I must admit that, when I look at community hospitals, I am never quite sure what the definition is; looking into the detail, I struggle to find any definition that the Government have come up with. Those are key questions about the leftward shift. I think we all agree that that would be welcome, but it is about the delivery plan. Of course, the 10-year plan has no delivery chapter, which again leads us back to the questions for the Minister today. I appreciate that this is not her portfolio, but these questions will keep coming time and again: how do we actually deliver, and what does this look like in the guise of neighbourhood health centres? On that point, when it comes to delivery, I would like to pose something to the Minister: it was reported in the news over the weekend that NHS capital spend could be under threat to fund the defence investment plan. I hope she will be able to stand at this Dispatch Box and say that that is categorically not true—but that is going to be important. That leads me on to another question that I would like to pose to the Minister. The response to a written question about the abolition of NHS England and its impact on services stated: “The abolition of NHS England is causing no disruption to the development of new services.” Will the Minister state that from the Dispatch Box? Certainly, from what we are hearing on the ground, the ICB changes—losing 50% through redundancies—are having a significant impact on the way in which services are planned and delivered. I am therefore keen to understand the rationale behind that statement. To finish where I started, community hospitals really are the healthcare that feels human. They are local, they are close to home and they are something that we across this House should aspire to. That family approach is where we all want to be; it is how we get there that is the question for the Government.

• 15 Jun 2026 · Defence Investment Plan · Hansard source

  More

  The Business Secretary said on the weekend that a lot of time and effort had gone into the defence investment plan, but when pushed he said that he had not read it. The former Defence Secretary and former Minister for the Armed Forces have read it, and they resigned. The Minister for Defence Readiness and Industry said that he had read it in full. Why did he decide not to resign when his two colleagues in the Department did resign?

• 9 Jun 2026 · Waiting Lists: Unreported Removals · Hansard source

  More

  Last month, the Health Service Journal reported that the elective waiting list target was met largely—largely—because a record number of patients were removed from waiting lists in March without receiving treatment. Can the Minister tell the House how many patients were removed in March and what happened to them, and whether she is satisfied that they definitely did not need treatment?

• 9 Jun 2026 · Waiting Lists: Unreported Removals · Hansard source

  More

  It is not just the Conservatives who are raising this issue; it is patients and the Health Service Journal . The answer is that 350,000 people—a city the size of Coventry—were wiped off the waiting list with no treatment, and that is 100,000 more than the month before. If there is genuinely nothing to hide, the Government should not worry about putting out the figures. Will the Minister commit to a review to find out what has happened to those 350,000 patients, or does she believe that waiting list targets should be met by removing patients from the figures rather than actually treating them?

• 4 Jun 2026 · Business of the House · Hansard source

  More

  Could we have a debate in Government time on performance and image-enhancing drugs? Last month, UK Anti-Doping released a survey that looked at 1,000 young people between the ages of 16 and 25; it showed that a third of them had taken IPEDs, and over 40% had seen repeated adverts for them online. This is a growing concern that I have been raising for the last number of years, and I am really concerned that the situation will get worse before it gets better. Could the Leader of the House use his offices to grant a debate on the subject in Government time, in which we could explore this issue as it relates to health, sport and education?

• 2 Jun 2026 · Community Pharmacies · Hansard source

  More

  The Minister points to the important partnership between community pharmacies and dispensing GPs. There are concerns about the change in the EMIS module and the future for dispensing practices. If the Minister does not have the answers here, will he write to me about what is happening with EMIS and where he is looking to take dispensing practices in the future?

• 2 Jun 2026 · Community Pharmacies · Hansard source

  More

  It is a pleasure to serve under your chairmanship, Ms Jardine, and I thank the hon. Member for Tiverton and Minehead (Rachel Gilmour) for securing this important debate. It is important that we discuss community pharmacies, given their place not only in the health landscape but in the hearts of many of my constituents and people across the nation. I, too, have visited multiple pharmacies, both in my shadow role and as an MP, and I, too, went to my local pharmacy for my flu jab, back in Newbold Verdon. I am very grateful to them because I found the system very easy to use and to get into. It is really important to see that system change that makes it more accessible and easier for people to make the choice to improve their own health and protect others. There are positives in this debate that we must celebrate. Community pharmacies are one of the most accessible parts of our health service. For millions of patients, particularly older ones, those with long-term conditions or those living in rural communities, the local pharmacy is often the front door to the NHS. They provide expert advice, dispense vital medicines, support prevention and increasingly deliver clinical services that help to reduce pressure on GPs and hospitals—as a former GP, I am very grateful for that—and that is why this debate is so important. Ministers want community pharmacies to do more, but I worry that, at the same time, they are actually making it harder for pharmacies to survive. This debate is timely, given that the Government agreed the community pharmacy contractual framework for 2026-27 last Friday. I expect that the Minister will reference that, but I will let Community Pharmacy England’s response speak for itself: “Accepting this deal does not mean we think it is enough—for this year or the future.” It went on to say: “It means the opposite…the sector is in a critical position, and that we now need urgent work on a sustainable long-term solution, including reform of the contract, funding and reimbursement model.” Given the Government’s enthusiasm for reviews and long-term plans, I would be grateful if the Minister updated us on what meetings he will have to work on the framework and the wider funding model, along with what changes we can expect and in what kind of time. The reality is that pharmacies continue to face mounting financial pressures, many related to the Government’s tax rises. Over the last two years, the Government have made a conscious choice not to exempt community pharmacies from their taxes and have even voted against that. In the first year of this Labour Government, pharmacies faced higher employer national insurance contributions alongside increases in the national living wage. In the second year, they have lost the temporary business rates support that they relied on, with the replacement not matching the rise in their costs. The sector is clear that much of the additional funding announced through the new framework will simply be absorbed by those rising costs. The headline findings from Community Pharmacy England’s latest “Pharmacy Pressures” survey, due to be published later this month, show that 100% of pharmacies report that costs are higher than at this time last year and that three quarters are losing money, while 86% say that it is taking longer to procure medicines and 76% say that patients are already being directly impacted by the pressures on their businesses. The National Pharmacy Association put it plainly last Friday when it said it was concerned that much of the funding increase will need to be spent on increased costs, including national living wage contributions, inflation and business rates rises, “rather than addressing chronic under-funding”. Those figures tell a simple story. The Government are asking pharmacies to do more while making it more expensive for them to keep their doors open. What discussions has the Minister had with the Chancellor regarding business rates for community pharmacies? Has he even raised the sector’s concerns with the Chancellor, and if so, what response did he receive? Will he press for a package of support similar to that made available to other sectors such as pubs, to help with those pressures? The rising costs also cast a shadow over the Government’s plan to expand independent prescribing through community pharmacy. We can all see that independent prescribing has enormous potential. It could improve patient access to care, make better use of pharmacists’ clinical expertise and help to deliver the Government’s ambition of shifting care from hospitals into the community. But the sector itself is not convinced that the necessary investment is in place. Community Pharmacy England has said: “we are not persuaded that sufficient investment is being made to enable the full and effective introduction of IP…given the workload, enhanced clinical responsibility, clinical governance and infrastructure requirements that it will entail.” It went on to warn that “the addition of IP to the CPCF risked being set up to fail.” That should concern us all in this Chamber. If pharmacies are expected to become a cornerstone of neighbourhood healthcare, as set out in the NHS 10-year plan, what steps are the Government taking to ensure that the necessary workforce, governance and infrastructure are in place to support that ambition? What response does the Minister have to those concerns, and what steps will he take to ensure that independent prescribing is the success we all want it to be? Alongside the financial pressures, pharmacies continue to face significant challenges in the medicine supply chain. Analysis by the National Pharmacy Association earlier this year highlighted rising prices for a number of cancer medicines and concerns about the impact on availability. At the same time, the number of medicine price concessions has reached record levels. There were 204 concessions agreed in April, surpassing the previous record set only a month earlier. Community Pharmacy England has now confirmed a new record of 219 concessions for May, with further requests still under negotiation. Behind those numbers are real patients facing delays, uncertainties and difficulties accessing the medicines that they need. Community Pharmacy England has warned that those figures reflect the continuing fragility of medicine supplies in the supply chain and that the wider instability from the middle east crisis is adding pressure. Of course, I cannot hold the Government responsible for that, but it is their duty to look at that volatility and to reassure patients and the sector that resilience is being put in place and measures are being looked at. I would be grateful for an update from the Minister on what that looks like. Before I conclude, I will raise an important point that is affecting dispensing practices. We have not talked about those today, but they are part of the real fabric of the community network. Dispensing GPs provide essential primary care medicine supplies to 10 million patients in remote, rural and coastal communities, where access to a community pharmacy is limited. For many patients, they are the primary point of access to medicines. Earlier this year, dispensing practices were informed that the central NHS England funding for the EMIS web dispensing module would cease and that the costs would instead be passed directly to the practices. The proposal generated significant concern among dispensing practices, the British Medical Association and the Dispensing Doctors’ Association. Concerns centred on the lack of consultation, the timing of the changes and the potential impact on the sustainability of dispensing services. Following representations from the sector, implementation has now been paused and central funding has continued. I welcome that decision. However, the uncertainty created caused understandable concerns for practices, their patients and the planning of future services, particularly for those in rural communities. When I wrote to the Minister to raise that issue, he responded that an assessment will take place this year of the long-term provision of dispensing modules and that NHS England will consult relevant bodies such as the Dispensing Doctors’ Association as part of that. Will the Minister provide further details on that assessment today? What criteria will be used? Who else is being consulted? If NHS England is going, who will take that work on? When can dispensing practices expect greater certainty about future arrangements? I would also be grateful if the Minister addressed concerns about the discount abatement—what is called the clawback system. Dispensing practices continue to argue that the current arrangement creates inequalities for them compared with community pharmacies. Equally, community pharmacies are upset about the clawback, so there is an obvious tension. Given that the Government are looking at the long-term structure, I would be grateful if the Minister took that away and considered how we can modernise that aspect to ensure that there is equity in the system as well as an understanding from both sides. Ministers have made it clear that they want pharmacies to play a greater role in prevention and neighbourhood healthcare and in reducing pressures elsewhere in the NHS. We in the Opposition agree, yet throughout this debate we have heard concerns from across the sector about rising costs, medicine supplies, independent prescribing and dispensing services. The question is whether Government policy is keeping pace with the expectations being placed on pharmacies, or whether Ministers are making it harder for the sector to deliver the growth and innovation they say they want to see. Community pharmacies have repeatedly demonstrated their value to patients in the wider health service. I therefore look forward to hearing from the Minister how he intends to address those concerns and provide greater confidence to a sector that remains vital to communities up and down this land.

• 2 Jun 2026 · Murder of Henry Nowak · Hansard source

  More

  “I’ve been stabbed” versus “He racially abused me.” How are the Government going to rebuild public confidence in our culture and in institutions that have attempted to rank people according to perceived oppression, rather than judging each person on their actions and on reality?

• 1 Jun 2026 · Lord Mandelson Humble Address: Government Response · Hansard source

  More

  On page 243 of volume II part III, the Minister’s predecessor, talking about Labour MPs, states: “Every meeting I have is ‘who can we tax in order to pay benefits to others’.” Is that the same experience the Minister is having in every meeting he has?

• 1 Jun 2026 · Equality Act 2010: Code of Practice · Hansard source

  More

  I am going to try to get some clarity, because my hon. Friend the Member for East Grinstead and Uckfield (Mims Davies) asked when there will be written explanations of the draft changes, as did my hon. Friend the Member for Reigate (Rebecca Paul). In both answers, the Minister talked about process. Well, process dictates that there should be written answers, so when will we see them in this House?

• 1 Jun 2026 · Health Bill · Hansard source

  More

  The Secretary of State is making himself the data controller of all the data that will be in place. What impact does that have on the sections he has just talked about?

• 20 May 2026 · Defence Readiness · Hansard source

  More

  I posed this question to the Minister’s colleague, the Minister for the Armed Forces, when he was last at the Dispatch Box: where is the DIP stuck? He seemed to point the finger at the Treasury, but can I get an update on where the DIP is actually stuck?